The Alliance for Regenerative Medicine’s annual Cell & Gene State of the Industry Briefing is a top-level gathering for key stakeholders in the field. This event includes ARM’s annual yearly update on the sector’s progress and two noteworthy sessions featuring top CEOs and executives highlighting future inflection points for cell and gene therapies in the coming year.
Over 800 of the cell and gene therapy field’s top stakeholders including company founders, C-level business executives, investors, media, patient advocates and academic leaders interested in learning more on the sector’s recent advances and outlook for the industry in the coming year.
2024 Cell & Gene State of the Industry Briefing Agenda
Introduction and Industry Update
Tim Hunt, CEO, Alliance for Regenerative Medicine
INDUSTRY UPDATE SLIDEDECK
Expediting the Development of Cell and Gene Therapy
Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration (FDA)
EXPEDITING THE DEVELOPMENT OF CGT SLIDEDECK
A Seminal Moment Arrives for Gene Therapy and Sickle Cell Disease – What’s Next?
Gbola Amusa, M.D., Partner, Chief Scientific Officer, Chardan (Moderator)
Samarth Kulkarni, Ph.D., CEO, CRISPR Therapeutics
Andrew Obenshain, CEO, bluebird bio